治疗慢性心力衰竭的Xinyang和Xinyin片的生物活性成分:药理动力学,网络药理学和实验验证
Yan-Ling Lan1, Si-Mian Chen2, Bin-Xin Dai2
1School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
Journal of integrative medicine
|January 9, 2026
概括
新阳片 (XYAT) 和新宁片 (XYIT) 通过调节关键信号通路,有效治疗慢性心力衰竭 (CHF). XYAT显示了活性化合物的优越系统暴露,支持其用于心血管健康的配方.
科学领域:
- 综合医学是一个整体的医学.
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 辛阳片 (XYAT) 和辛宁片 (XYIT) 是已确立的慢性心力衰竭 (CHF) 治疗方法.
- 了解它们的药理动力学物质基础和机制对于优化它们的使用至关重要.
研究的目的:
- 调查XYAT和XYIT的药学动力学材料基础.
- 阐明治疗慢性心力衰竭 (CHF) 的基本作用机制.
- 为了比较XYAT和XYIT的药理动力学概况和治疗疗效.
主要方法:
- 使用UPLC-HRMS和HPLC-MS/MS进行化合物识别和药理动力学分析.
- 使用网络药理学来预测治疗点和途径.
- 通过流式细胞计,西部斑块和体外/体内模型验证了目标和机制.
主要成果:
- 在XYAT和XYIT中识别和量化了许多化合物,XYAT对关键成分的系统暴露率更高.
- 网络药理学确定了七种候选活性化合物,针对和PI3K/Akt信号通路.
- XYAT和XYIT证明了通过已识别的生物活性化合物介导的抗氧化应激和心脏毒性保护作用.
结论:
- 通过调节和PI3K/Akt信号通路,XYAT和XYIT可以缓解慢性心力衰竭 (CHF).
- 活性成分的优异系统暴露支持XYAT用于心血管应用的配方.
- 综合方法提供了机制性的见解,并验证了这些传统中医药的治疗潜力.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
518
12:34Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
1.2K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:22Heart Failure Drugs: Diuretics
789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
01:22Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758